Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Bortezomib (Velcade®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2814. 2014 Authors' conclusions Bortezomib (Velcade®) is recommended as an option for restricted use within NHS Wales for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation. Bortezomib (Velcade®) should be restricted for use in combination with dexamethasone. This recommendation applies only in circumstances where the approved Patient Access Scheme is utilised. Bortezomib (Velcade®) is not recommended for use within NHS Wales in combination with pegylated liposomal doxorubicin. Indexing Status Subject indexing assigned by CRD MeSH Adult; Antineoplastic Agents; Boronic Acids; Humans; Multiple Myeloma; Pyrazines Language Published English Country of organisation Wales English summary An English language summary is available. Address for correspondence All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Email: AWTTC@wales.nhs.uk AccessionNumber 32014001451 Date abstract record published 22/12/2014 |